Acoramidis

How it works

It binds selectively to the thyroxine-binding sites of transthyretin, stabilising the tetramer and preventing its dissociation into amyloidogenic monomers.

Prescribing in practice

• It is a disease-modifying therapy for transthyretin amyloid cardiomyopathy and is not a substitute for standard heart failure management, which should continue as indicated.
• Treatment is generally initiated and supervised within a specialist amyloidosis or cardiology service.
• Diagnosis of transthyretin amyloid cardiomyopathy should be confirmed before starting therapy.

Monitoring

Monitor cardiac status and functional capacity within the specialist service to assess ongoing response to treatment.

Counselling the patient

• This medicine aims to slow progression of the underlying heart condition and is taken long term.
• Continue your other heart medicines and attend specialist follow-up appointments.

Evidence & guidelines

Acoramidis was evaluated for transthyretin amyloid cardiomyopathy in the ATTRibute-CM trial, which informed its licensed use.